Nociceptive Pain Definition vs Neuropathic Pain: Matching the Drug

Nociceptive pain comes from damaged or threatened tissue, such as an arthritic joint, sent through healthy nerves. Neuropathic pain comes from injury or disease of the nerves themselves. The two respond to different medicines. One woman’s knee replacement worked, yet her shin still burned. A fingertip over a small skin nerve crossing the scar found the real source.

Her new knee was two years old. By every surgical yardstick, it was a success. The pain was still worse than before the operation. It burned down the inner shin. It flared when a bedsheet brushed the skin. It did not care whether she had walked or rested. Anti-inflammatories and opioids had done nothing, and her chart used the word failed. One fingertip pressed below the joint line, over a small skin nerve crossing the scar, found the real source.

The nociceptive pain definition is the right starting point, because the medicine that helps depends on which kind of pain you have. Many patients carry the other kind, and no one ever names it. The video above, Nerve or Joint? Pain Speaks Two Languages, is Chapter 20 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD.

What is nociceptive pain, and how is it different from neuropathic pain?

The International Association for the Study of Pain defines nociceptive pain as pain from real or threatened damage to tissue that is not nerve. Pain sensors fire and send the signal. Neuropathic pain is caused by a lesion or disease of the nervous system that carries feeling. The first is a working smoke detector reporting a real fire. The second is a detector whose own wiring is burning. A third type, nociplastic pain, is an amplifier in the brain and spinal cord with no lesion to find. It is explained in why nonspecific is not a diagnosis. One person can carry two at once. That overlap is called mixed pain.

How do doctors diagnose nerve pain at the bedside?

Nerve pain is graded, not found by one test. A past injury or disease, with pain in a pattern that fits the nerve map, earns the grade possible. Matching signs on the exam in that same area earn probable. Probable is usually enough to start treatment. A test that confirms it earns definite. The most telling sign is loss of feeling, though pain from light touch can be the only finding. A doctor who never touches the leg cannot get past possible. The exam takes about ninety seconds.

Questionnaires help decide where to press. She scored 21 out of 38 on one. It has a sensitivity of 85 percent and a specificity of 80. So it misses some nerve pain and flags some that is not. What standard electrical nerve testing can and cannot show is covered in what EMG and nerve conduction studies measure.

How often is nerve pain hidden inside a joint or disc diagnosis?

Far more often than its treatment suggests. Across 14,269 people with back pain, 47 percent had a nerve part to their pain. That rose to 60 percent when pain ran into the leg. It fell to 27 percent when it did not. Some people still had pain three months after a knee replacement. Of those, 53 to 74 percent screened as nerve pain, based on the questionnaire. In 56 percent of them, it lasted through the next year. In British family practice, only 4.5 percent of chronic pain had ever had a fair trial of one drug made for nerve pain.

Some of it is a trapped nerve filed under the spine. Among 834 low back pain patients in a row, 14 percent met criteria for a superior cluneal nerve disorder. In 68 percent of those, up to three nerve blocks relieved more than half their pain. The wider search for what drives pain after joint replacement is laid out in finding the real driver of persistent knee replacement pain.

What a damaged nerve does to the medicine

An injured nerve does not go quiet. In painful polyneuropathy, 40.5 percent of recorded C-fibers fired on their own. In the painless kind, it was 14.6 percent. In people with diabetes, 72 percent of pain fibers fired on their own in painful neuropathy. In painless neuropathy, it was 15 percent. In diabetic mice, that firing tracked methylglyoxal, a toxin made from sugar. That is the metabolic driver. The second driver sits at the receptor. After nerve injury, damaged nerve cells turn down the genes for their own opioid receptors. About two in three nerve pain patients on current treatment say their pain is poorly controlled. The target has stopped listening.

Damaged nerves also fail in different patterns. In one study, 902 patients with nerve pain outside the brain and spine had standard sensory testing. Of them, 42 percent showed loss of feeling. Another 33 percent showed irritable pain sensors. And 24 percent had small-fiber loss with pain to light touch. Those patterns predicted which drug helped.

Does all pain live in the brain?

The strongest opposing view says the source hardly matters, because pain is felt in the brain. But brain scan patterns of pain light up for any striking event. They do it even in people born unable to feel pain. Scan patterns built for chronic pain told back pain patients from healthy people only 71 to 73 percent of the time. No scan tells nociceptive from neuropathic pain in a clinic.

The deciding evidence points to the periphery, out at the nerves. Fourteen patients had painful peripheral neuropathy, nerve damage outside the brain and spine. A nerve block below the knee wiped out the pain in every one, in a median of ten minutes. The numbing drug in the blood was too low to touch the brain. In 31 amputees, weak numbing drug on the dorsal root ganglion put out phantom limb pain. That ganglion is the cluster of nerve cell bodies just outside the spine. Pain is felt in the brain. Yet in these patients, it was being made out at the nerve.

Which medicines work for nerve pain, and why does the wrong one keep winning?

For nerve pain, oral anti-inflammatories have two small studies and no sign of real relief. Acetaminophen, with or without codeine, has no qualifying study at all. Across 96 trials in chronic non-cancer pain, opioids beat placebo by 0.69 centimeters on a ten-centimeter scale. That is less than the smallest change a patient can feel. The drugs made for nerves are better, but modest. In the 2025 update, the number needed to treat was 4.6 for tricyclics, 7.4 for SNRIs, and 8.9 for gabapentinoids. Across 9 trials of anticonvulsants for low back pain and sciatica, 14 of 15 comparisons showed no effect. Diclofenac at 150 milligrams a day moved knee and hip arthritis pain by a standardized 0.57.

Take a Swedish region of 1.7 million people. Patients with lumbar spinal stenosis, a nerve diagnosis, were more often on an opioid than a nerve drug, 67.1 against 40.6 percent. Take 22,037 Medicare patients with a new diabetic neuropathy diagnosis. Within a year, 23.42 percent started an opioid, while 4.56 percent started gabapentin. Part of the reason is money. Short visits reward the default prescription. The ninety-second exam that sorts the two languages is the first thing a crowded schedule drops. None of this is a reason to change a medication on your own. It is a reason to ask your physician which kind of pain each drug on your list is meant to treat.

Matching the intervention to the mechanism

Once the cause is named, treatment can aim at the source. In an open-label, industry-sponsored trial, stimulating the dorsal root ganglion worked in 81.2 percent at three months. Standard spinal cord stimulation worked in 55.7 percent. Options that destroy a nerve belong last, because a cut nerve can become the next pain source. That is exactly what had happened to her.

She did not get a revision. A second diagnostic block confirmed the nerve. Then came a series of blocks and pulsed radiofrequency, done awake. Duloxetine came first. Gabapentin was added when that only partly worked, at lower doses of each. A high-concentration capsaicin patch went on the strip of shin the bedsheet had tormented. With her physicians watching, she came off the oxycodone in eleven weeks and the meloxicam in one. Her A1c was 6.4. Bringing blood sugar down with food and daily walking matters here, because toxins made from sugar help keep injured fibers firing. I have watched good physicians treat a nerve as if it were a joint, and I have done it myself. Why nobody caught this sooner connects to what doctor reviews measure and miss, and why the mind and the metabolism cannot be separated comes next. Each study and its limits are in the Chapter 20 Deep Dive.

Frequently asked questions

What is the difference between nociceptive and neuropathic pain?

Nociceptive pain comes from damaged or threatened tissue, such as an arthritic joint. It sends signals through healthy nerves. Neuropathic pain comes from injury or disease of the nerves themselves, so the wiring is the problem. They respond to different medicines, and many people have both. A doctor sorts them with your history and a hands-on exam, not a scan. A broader overview of pain categories is in types of pain and why the category changes the treatment.

Why does my knee still hurt after a successful replacement?

A well-placed implant can still leave pain from another source. Some people still hurt three months after a knee replacement. Of those, 53 to 74 percent screened positive for nerve pain. It often comes from small skin nerves crossing the scar. Pressing along the nerve and a small numbing shot can show whether it is the source. That comes before anyone talks about a revision. One way that nerve is tested and treated is described in what a 60-day nerve stimulator is actually testing.

What does nerve pain feel like?

People often describe burning, electric or shooting pain. Something as light as clothing or a bedsheet can hurt. The same area may be numb. It often wakes people at night. Loss of feeling on the exam is the most telling sign. A common example is explained in why diabetic nerve pain burns at night.

Do anti-inflammatories help nerve pain?

The evidence says probably not. Cochrane reviewers found only two small studies of oral anti-inflammatories for nerve pain. They found no sign of real relief. Yet surveys found 18 to 47 percent of people with nerve pain taking them for it. Any change to a medication belongs in a conversation with your physician. Hidden causes of nerve damage are worth ruling out too, including vitamin B12 neuropathy that a normal level can miss.

Can a trapped nerve be mistaken for back pain?

Yes. In one series of 834 low back pain patients in a row, 14 percent met criteria for a superior cluneal nerve disorder. That is a small nerve crossing the rim of the pelvis. Nearly half of those had leg symptoms that looked like a spine problem. Up to three nerve blocks relieved more than half the pain in 68 percent of them. Diagnosis and treatment of that nerve are covered on the cluneal neuropathy page.

Sources

1. International Association for the Study of Pain (2020). IASP Terminology (revised definitions: nociceptive, neuropathic, nociplastic pain; allodynia; hyperalgesia). IASP website. https://www.iasp-pain.org/resources/terminology/
2. Finnerup, N. B., Haroutounian, S., Kamerman, P., Baron, R., Bennett, D. L. H., Bouhassira, D., Cruccu, G., Freeman, R., Hansson, P., Nurmikko, T., Raja, S. N., Rice, A. S. C., Serra, J., Smith, B. H., Treede, R. D., & Jensen, T. S. (2016). Neuropathic pain: an updated grading system for research and clinical practice. Pain, 157(8), 1599–1606. https://doi.org/10.1097/j.pain.0000000000000492
3. Gudala, K., Bansal, D., Vatte, R., Ghai, B., Schifano, F., & Boya, C. (2017). High Prevalence of Neuropathic Pain Component in Patients with Low Back Pain: Evidence from Meta-Analysis. Pain Physician, 20(5), 343–352. https://pubmed.ncbi.nlm.nih.gov/28727698/
4. Bertram, W., Howells, N., White, S. P., Sanderson, E., Wylde, V., Lenguerrand, E., Gooberman-Hill, R., & Bruce, J. (2024). Prevalence and patterns of neuropathic pain in people with chronic post-surgical pain after total knee arthroplasty. Bone & Joint Journal, 106-B(6), 582–588. https://doi.org/10.1302/0301-620X.106B6.BJJ-2023-0889.R1
5. Becker, A. K., Babes, A., Düll, M. M., Khalil, M., Kender, Z., Gröner, J., Namer, B., Reeh, P. W., & Sauer, S. K. (2023). Spontaneous activity of specific C-nociceptor subtypes from diabetic patients and mice: Involvement of reactive dicarbonyl compounds and (sensitized) transient receptor potential channel A1. Journal of the Peripheral Nervous System, 28(2), 202–225. https://doi.org/10.1111/jns.12546
6. Baron, R., Maier, C., Attal, N., Binder, A., Bouhassira, D., Cruccu, G., Finnerup, N. B., Haanpää, M., Hansson, P., Hüllemann, P., Jensen, T. S., Freynhagen, R., Kennedy, J. D., Magerl, W., Mainka, T., Reimer, M., Rice, A. S. C., Segerdahl, M., Serra, J., … Treede, R. D. (2017). Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain, 158(2), 261–272. https://doi.org/10.1097/j.pain.0000000000000753
7. Haroutounian, S., Nikolajsen, L., Bendtsen, T. F., Finnerup, N. B., Kristensen, A. D., Hasselstrøm, J. B., & Jensen, T. S. (2014). Primary afferent input critical for maintaining spontaneous pain in peripheral neuropathy. Pain, 155(7), 1272–1279. https://doi.org/10.1016/j.pain.2014.03.022
8. Soliman, N., Moisset, X., Ferraro, M. C., de Andrade, D. C., Baron, R., Belton, J., Bennett, D. L. H., Calvo, M., Dougherty, P., Gilron, I., Hietaharju, A. J., Hosomi, K., Kamerman, P. R., Kemp, H., Enax-Krumova, E. K., McNicol, E., Price, T. J., Raja, S. N., Rice, A. S. C., … Haroutounian, S. (2025). Pharmacotherapy and non-invasive neuromodulation for neuropathic pain: a systematic review and meta-analysis. Lancet Neurology, 24(5), 413–428. https://doi.org/10.1016/S1474-4422(25)00068-7
9. Nyqvist, L., Åkerstedt, J., & Thoreson, O. (2024). Current trends in the medical treatment of neuropathic low back pain: a Swedish registry-based study of 1.7 million people. BMC Musculoskeletal Disorders, 25(1), 486. https://doi.org/10.1186/s12891-024-07599-4
10. Deer, T. R., Levy, R. M., Kramer, J., Poree, L., Amirdelfan, K., Grigsby, E., Staats, P., Burton, A. W., Burgher, A. H., Obray, J., Scowcroft, J., Golovac, S., Kapural, L., Paicius, R., Kim, C., Pope, J., Yearwood, T., Samuel, S., McRoberts, W. P., … Mekhail, N. (2017). Dorsal root ganglion stimulation yielded higher treatment success rate for complex regional pain syndrome and causalgia at 3 and 12 months: a randomized comparative trial. Pain, 158(4), 669–681. https://doi.org/10.1097/j.pain.0000000000000814

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 20 of The Pained Brain by Dr. Padda and Dr. KrisJay Fucanan, MD. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP